Allergan Archives -

New York’s attorney general has accused Teva of lying to evade responsibility for its alleged role in fuelling

New York says Teva lied about role in opioid epidemic

https://pharmaphorum.com/news/new-york-says-teva-lied-about-role-in-opioid-epidemic/

News/ News/ Sales and Marketing

Allergan, Teva considering $5bn play to shake off opioid hangover

Phil Taylor AbbVie, Allergan, litigation, opioid crisis, Teva 0 Comment

AbbVie’s Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid

Allergan, Teva considering $5bn play to shake off opioid hangover

https://pharmaphorum.com/news/allergan-teva-considering-5bn-play-to-shake-off-opioid-hangover/

News/ News/ Sales and Marketing

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

Phil Taylor ABPI, Allergan, AstraZeneca, Britannia Pharma, GlaxoSmithKline, PMCPA, Sanofi 0 Comment

AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi, Allergan and Britannia Pharma have been reprimanded for running advertisements that breached the

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

https://pharmaphorum.com/news/latest-abpi-code-breaches-reveal-the-risk-of-likes-on-linkedin/

News/ News/ Sales and Marketing

AbbVie prices first presbyopia drug Vuity at $80 per month

Phil Taylor AbbVie, Allergan, ophthalmology, presbyopia, pricing, Vuity 0 Comment

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight

AbbVie prices first presbyopia drug Vuity at $80 per month

https://pharmaphorum.com/news/abbvie-prices-first-presbyopia-drug-vuity-at-80-per-month/

Market Access/ News/ News

AbbVie claims first FDA okay for presbyopia drug therapy

Phil Taylor AbbVie, Allergan, fda, ophthalmology, presbyopia, regulatory approval 0 Comment

The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that

AbbVie claims first FDA okay for presbyopia drug therapy

https://pharmaphorum.com/news/abbvie-claims-first-fda-okay-for-presbyopia-drug-therapy/

News/ News/ R&D

Allergan builds case for first drug therapy for presbyopia

Phil Taylor AbbVie, Allergan, Eyenovia, LENZ Therapeutics, Novartis, Ocuphire, ophthalmology, Orasis Pharma, presbyopia, Visus Therapeutics 0 Comment

If you are middle aged and find you have to hold your phone at arm’s length to read,

Allergan builds case for first drug therapy for presbyopia

https://pharmaphorum.com/news/allergen-builds-case-for-first-drug-therapy-for-presbyopia/

News/ News/ Sales and Marketing/ Top stories

Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company

Phil Taylor Allergan, Brent Saunders, M&A, SPAC, Vesper Healthcare Acquisition 0 Comment

Brent Saunders has been out of the limelight for a few months since departing Allergan after its takeover

Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company

https://pharmaphorum.com/news/ex-allergan-ceo-saunders-pops-up-again-in-blank-cheque-company/

News/ News/ Sales and Marketing

Saunders steps aside as AbbVie closes in on Allergan merger

Phil Taylor AbbVie, Allergan, Mergers and acquisitions, regulatory 0 Comment

The US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by

Saunders steps aside as AbbVie closes in on Allergan merger

https://pharmaphorum.com/news/saunders-steps-aside-as-abbvie-closes-in-on-allergan-merger/

News/ News/ R&D

First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug

Phil Taylor Allergan, blindness, CRISPR/Cas9, Editas, gene editing, Leber’s Congenital Amaurosis, ophthalmology 0 Comment

A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9,

First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug

https://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/

Trending

Allergan

Login